XENE Q2 2024 Earnings — Xenon Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

XENEXenon Pharmaceuticals Inc.

$5B

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$69M

Net Income

-$58M

EPS (Diluted)

$-0.75

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$33M

Free Cash Flow

-$34M

Stock-Based Comp.

$15M

Balance Sheet

Total Assets

$884M

Total Liabilities

$40M

Stockholders' Equity

$844M

Cash & Equivalents

$137M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$69M	-$56M	-24.2%
Net Income	-$58M	-$47M	-22.0%